NCT00966706View on ClinicalTrials.gov

Cisplatin, Capecitabine, Gemcitabine and Epirubicin or Docetaxel for Patients With Stage III or IV Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

April 30, 2009

Study Completion Date

October 31, 2009

Conditions
Pancreatic Cancer
Interventions
DRUG

capecitabine

Given systemically

DRUG

cisplatin

Given systemically

DRUG

docetaxel

Given systemically

DRUG

epirubicin hydrochloride

Given systemically

DRUG

gemcitabine hydrochloride

Given systemically

Trial Locations (1)

20132

San Raffaele Scientific Institute, Milan

All Listed Sponsors
lead

IRCCS San Raffaele

OTHER

NCT00966706 - Cisplatin, Capecitabine, Gemcitabine and Epirubicin or Docetaxel for Patients With Stage III or IV Pancreatic Cancer | Biotech Hunter | Biotech Hunter